NASDAQ
1.09USD
-0.02 (-1.82%)
We have scored 5 news catalysts on Decoy Therapeutics Inc. (DCOY) over the past 12 months. The biggest single-day move next to one of them came Jan 13, 2026, when DCOY closed +53.4%: “Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform”. Coverage across the window leans positive (average ticker sentiment +0.62). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
574.5K
P/E
—
EPS
—
Beta
0.58
52W range
0.9-20.76
Day range
1.07–1.10
Open
1.10
Prev close
1.11
Volume
12.5K
Avg volume
1.7M
Dividend
0.00
IPO
2015-01-29
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Decoy Therapeutics Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for DCOY: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
